Vision & Mission
Combining cancer vaccines
and T-cell therapies
ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.
We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).
Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.
Download the presse release Lyon, France – June 15, 2023 – ErVaccine Technologies, a French biotechnology company developing next-generation...
Download the press release Lyon, France – February 23, 2023 – ErVaccine Technologies, a French biotech company developing next-generation...
ErVimmune closes a €4.5 million financing round and prepares to start clinical trial with its first therapeutic cancer vaccine in 2023
ErVaccine is developing a therapeutic vaccine and cell therapy technology potentially applicable to many types of cancers First vaccine candidate...
Publications & abstracts
Research Article in Science Advances 2022- Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy
SITC 2021 – Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy
Medical research and development, in particular the development of new families of tumour antigens.
Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.
> Publications & abstracts
> Recent news
> Legal notice
> About us
> Join us
28 RUE LAENNEC
69008 LYON FRANCE
+33 6 67 67 44 97